Vascular liver diseases (VLD) are a group of rare liver disorders consequence of alterations in the liver venous tree and of unknown etiology.
SARS-CoV-2 pandemic has led to a huge number of research studies in patients with liver disease that have demonstrated an increased risk of severe disease and death in patients with chronic liver disease (CLD). However, data on COVID-19 susceptibility, thrombotic risk and outcome in patients with VLD is not totally known.
In the last months, the Pfizer/BioNTech® BNT162b2 mRNA, Moderna® mRNA-1273, and the AstraZeneca®/University of Oxford ChAdOx1-nCoV-19 chimpanzee adenovirus vector vaccines have each reported excellent safety profiles have all gained rapid regulatory approval.
Due to the impact of SARS-CoV-2 in patients with CLD and the safe profile of vaccines, the European Reference Network (ERN) for hepatological disorders recommend and encourage vaccination of patients with rare liver disorders, including (VLD) (https://rare-liver.eu).